Friday, July 10, 2026

Drug profile · INN

paromomycin sulfate

paromomycin sulfate (HUMATIN) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — paromomycin sulfate
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

paromomycin sulfate (HUMATIN) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN paromomycin sulfate
Brand HUMATIN
Mechanism Bacterial 70S ribosome inhibitor
Target Bacterial 70S ribosome
Route ORAL
Formulation CAPSULE

Mechanism of action

Bacterial 70S ribosome inhibitor

Primary target: Bacterial 70S ribosome

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Omomyc Phase 2 · George Institute for · Advanced High-Grade Osteosarcoma

Related & competitor drugs

  1. azithromycin Bacterial 70S ribosome inhibitor
  2. chloramphenicol Bacterial 70S ribosome inhibitor
  3. clarithromycin Bacterial 70S ribosome inhibitor
  4. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  5. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin phosphate Bacterial 70S ribosome inhibitor

Frequently asked questions

What is paromomycin sulfate?

paromomycin sulfate (HUMATIN) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for paromomycin sulfate?

HUMATIN is a marketed brand name for paromomycin sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of paromomycin sulfate?

paromomycin sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.